IDEAYA Biosciences Announces Successful US FDA Type Meeting on Designs for Phase III Registration to Support the Agreed Potential and Full Approval of IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas - Comendocrine Carcinomas - Comendocrine Carcinomas - Com.